Jump Financial’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-10,830
Closed -$230K 2485
2026
Q1
$230K Sell
10,830
-160,362
-94% -$3.21M ﹤0.01% 1603
2025
Q4
$2.79M Buy
171,192
+85,899
+101% +$1.3M 0.03% 558
2025
Q3
$997K Sell
85,293
-955,758
-92% -$12.5M 0.01% 1022
2025
Q2
$12.1M Buy
1,041,051
+588,769
+130% +$5.37M 0.13% 201
2025
Q1
$3.95M Buy
452,282
+267,181
+144% +$3.37M 0.05% 391
2024
Q4
$2.66M Buy
185,101
+22,789
+14% +$360K 0.06% 432
2024
Q3
$3.67M Buy
162,312
+133,280
+459% +$2.76M 0.07% 306
2024
Q2
$565K Sell
29,032
-77,514
-73% -$2.03M 0.01% 1085
2024
Q1
$4M Buy
106,546
+74,743
+235% +$3.28M 0.11% 198
2023
Q4
$1.78M Sell
31,803
-42,052
-57% -$1.83M 0.06% 431
2023
Q3
$3.05M Buy
73,855
+56,307
+321% +$2.93M 0.11% 231
2023
Q2
$980K Buy
+17,548
New +$950K 0.04% 688
2023
Q1
Sell
-20,888
Closed -$761K 2076
2022
Q4
$761K Sell
20,888
-62,591
-75% -$2.05M 0.04% 600
2022
Q3
$2.38M Buy
83,479
+14,953
+22% +$570K 0.09% 325
2022
Q2
$3.1M Buy
+68,526
New +$3.56M 0.13% 209
2022
Q1
Sell
-3,344
Closed -$499K 1923
2021
Q4
$499K Buy
+3,344
New +$512K 0.03% 654

Other funds holding TXG

Jump Financial's TXG Position: Q2 2026 in Review

Jump Financial sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 10,830 shares — an estimated $230K sold.

Jump Financial first reported a position in TXG in Q4 2021 and held it in 16 quarters. The position peaked at $12.1M in Q2 2025. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Jump Financial reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
  • Jump Financial sold 10,830 10x Genomics shares in Q2 2026, an estimated $230K.
  • Jump Financial first reported a position in 10x Genomics in Q4 2021 and held it in 16 quarters.
  • Jump Financial's 10x Genomics position peaked at $12.1M in Q2 2025.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.